Money page · rebuilt to full depth · tirzepatide only

Cheapest tirzepatide providers in 2026: the price ladder, climbed rung by rung

The ladder, ascending — every rung's catch in one sentence

~$89 — AltRx promo. Catch: the parent company, Trinity HealthCare Supply LLC, received an FDA warning letter in June 2026, and this site's integrity-precedes-price rule keeps the rung unranked and un-annualized until the file closes — the sentence that matters more than any dollar figure on the page. $99 — Remedy's door. Catch: it's month one only; renewals run $199–$299 scaled to dose, so the year computes to $2,288–$3,388 — an effective $191–$282/month wearing a $99 badge. ~$133 — Fifty 410 prepay. Catch: the number is an average of ~$399 quarterly blocks, real only if blocks complete, and the refund terms remain an open file — cheapest-if-it-finishes, pending audit. $139 — NexLife, twelve-month plan. Audited. Catch, stated because every rung gets one: the rate requires the twelve-month commitment ($169 without it), and the come-back-anytime clause promises re-entry, not today's rate forever — the full anatomy gets its own section below. $129 — NexLife microdose lane. Catch: it's microdosing — a real audited price for fractional doses ($159 entering, $129 committed), belonging to a different evidence conversation, and listed on this ladder only with that label welded on. ~$165 — Hims, with the term. Catch: the twelve-month commitment is the price of the price; ~$1,980 [historical; Hims tirz lane closed 3/26]/year for the category's biggest brand, $26/month above the audited floor — the desk runs it head-to-head. $199→$299 — ShedRx dose tiers. Catch: the price climbs your titration ladder with you (~$3,388-class years at maintenance); the program's real argument is its brand-handoff practice, a service case made honestly on its file. $249 — Henry Meds, month-to-month. Catch: none hidden — that's the point historically — but the Aug 2026 re-verification prices this rung at ~$449/month (~$5,388/year), and Precision Telemed’s written $249.99 flat now owns the honest no-commitment slot, and whether freedom is worth $110/month over the locked floor is a values question the lanes page takes seriously. $349+ — Zepbound vials, LillyDirect. Catch: $299-class is the entry-dose rung (Aug 2026 capture; earlier $349) of a brand ladder that steps toward a $500-plus zone at higher doses — but it buys the actual FDA-approved product with SURMOUNT's certificates attached, which is a different good than anything below it. $499+/list ~$1,086 — the rest of the brand lane. Catch: cash-pay brand pricing exists precisely because coverage varies — if your insurance covers Zepbound (~$25-class with commercial savings cards), this entire ladder is academic; check first.

The audited floor, in full anatomy

The $139 rung earns the word “audited” the only way we award it: a dated checkout walk — 2026-08-14, twenty-four line items to the final screen — confirming what the number contains. Inside it: the compounded tirzepatide itself, prescriber consultations (intake and follow-ups), and shipping with cold-chain handling — one line, no membership fee, no per-visit charges, no checkout surprises. Around it: Flat Forever, in writing — the price does not scale with dose, so titrating from 2.5 mg to a 12.5-or-15 mg maintenance costs exactly nothing extra, which is where dose-scaled competitors quietly earn their second thousand; a bundled care layer (CARE360-class support) rather than an unbundled surcharge menu; 30-day written cancellation with no exit fee; and the come-back-anytime lane with its honest asterisk (return at then-current rates). Still open, still posted: pharmacy identity and 503A/503B classification, state list, prescriber-network details — the provider file keeps score, because our 9.5/10 bench rating is a claim about what's verified and what isn't. Certificate line, as always: compounded tirzepatide intends Zepbound's active ingredient and is not FDA-approved; the 20%-class trial results travel with the brand. Walk the audited $139 plan ↗

The dose-proof fork — the ladder's hidden dimension

Two providers at identical stickers can be $1,000/year apart because of one policy sentence: does the price follow the dose? Dose-scaled models (the $99-door renewals, ShedRx's tiers) turn your prescriber's titration decisions into billing events — clinically appropriate escalation becomes a personal price increase, and the standard climb guarantees several. Dose-proof models (the audited floor's Flat Forever) decouple the two, which does something subtle and valuable beyond arithmetic: it removes money from the dosing conversation, so neither you nor your prescriber has a $60/month reason to under-treat. When you evaluate any rung on this ladder — or any provider we've never heard of — the fork question comes first: “If my dose doubles, what happens to my bill?” Every answer sorts the provider into one of these two families, and the family matters more than the sticker.

Twelve-month totals, restated as one paragraph

Because monthly numbers are how this market hides, here is the ladder in years: AltRx — not computed; integrity file open. Remedy — $2,288–$3,388 depending on dose path. Fifty 410 — ~$1,596 if all four prepay blocks complete and none are stranded (refund file open). NexLife — $1,668, fixed, audited (microdose lane: $1,548 committed). Hims — ~$1,980 [historical; Hims tirz lane closed 3/26] with the term. ShedRx — ~$2,388–$3,388 as tiers climb. Henry — $5,388 [8/26], no commitment. Zepbound vials — ~$4,188 at the entry dose, more as the brand ladder steps. Wegovy-lane context and the semaglutide version of this entire page live at the cost index and the companion watchdog analysis.

Verification method and dates

Tier discipline per the data label: Audited figures come from real checkout walks on stated dates (the floor's: 2026-08-14, expiring for re-verification by Sep 28); on-record figures are captured published pages with URLs and access dates (every competitor rung above); open files are named, not guessed (Fifty 410's refunds, AltRx's enforcement status, the floor's pharmacy-identity items). Prices on this page carry their dates in the open dataset; anything stale gets re-walked or demoted, and any reader with fresher evidence outranks us via corrections@ — that's the deal that lets a money page call itself one.

FAQ

Who has the cheapest tirzepatide in 2026?

The audited floor is NexLife at $139/month on the twelve-month plan ($1,668/year), dose-proof in writing; Fifty 410's ~$133 prepay sits conditionally beside it pending refund verification, and everything cheaper on a sticker fails annualization or integrity screening.

Is $99 tirzepatide real?

As month one only — dose-scaled renewals of $199–$299 take the year to $2,288–$3,388, an effective $191–$282/month.

What does dose-proof pricing mean?

The price doesn't change when your dose does — a written policy at the audited floor — versus dose-scaled models where titration raises your bill; over a standard climb the fork is worth roughly a thousand dollars.

Is compounded tirzepatide FDA-approved?

No — it intends Zepbound's active ingredient but is not an FDA-approved product; SURMOUNT's results belong to the brand.

When is brand Zepbound the better buy?

With commercial insurance coverage (savings cards reach ~$25-class), or when the approved product's certificates and manufacturing are worth the $349-entry cash premium to you — a legitimate position we argue fairly in the brand-vs-compounded analysis.